THEON announces new strategic US and European investments and partnerships to build global leadership in Digital and Augmented Reality defense optronics domain under the THEON NEXT initiative
Bloomberg (THEON:NA) / Reuters (THEON.AS) Strategic Investment and Partnership with KOPIN Corporation – Augmented Reality System Development
Long-Term Supply Agreement with eMagin Corporation – OLED Displays
Strategic Industrial Partnership with ALEREON – Wireless Communication
Extending AR-MR-VR Capability via Investment in VARJO
11 August, 2025 – Theon International Plc (THEON) is proud to announce new strategic investments and strategic partnerships as part of its THEON NEXT initiative, building a platform to drive the development of next-generation soldier systems through targeted investments, collaborations, and co-development initiatives.
With a focus on the creation of innovative Digital and Augmented Reality (AR) solutions THEON NEXT aims to onboard best-in-class partners in their field of expertise to help shaping the future of operational dominance in modern warfare environments. To this end, THEON is announcing four major investments / strategic cooperations in the United States and Europe, marking a significant milestone in its journey to continue being a global leader in man-portable electro-optics. These transactions reinforce THEON's commitment to innovation, supply chain security, and transatlantic cooperation in defense technologies.
Following the establishment of a leading position in night vision systems, THEON has successfully expanded into thermal and digital solutions with its new A.R.M.E.D. product family. Similarly to the approach adopted for traditional Night Vision systems, favoring vertical integration and long-term supply agreements, THEON is now proactively stepping further into the rapidly growing Digital and AR domain, which relies on three critical technologies: Augmented and Virtual Reality Software – the foundation of next-generation soldier systems, enabling immersive situational awareness, enhanced decision- making, and digital overlays in real-world environments. Micro-displays – essential for next generation visual augmentation systems, with a strategic focus on developing a US-European microLED technology. Near-Range Wireless Connectivity – enabling seamless, cable-free integration of soldier gear with real-time data transmission.
To successfully face these challenges, THEON announces four major initiatives and agreements that not only constitute relevant milestones in its technological roadmap but also deepen the US-European industrial cooperation:
First, THEON is investing a total of $15 million in Kopin Corporation (KOPIN, NASDAQ: KOPN), a US-based defense micro-display and sub-system specialist with operations in the US and Scotland, UK. This comprises a $7 million interest bearing loan, convertible in preferred stock of KOPIN at a share price range of $3 to $4.5 in THEON's option, and $8 million capital increase for the acquisition of a 49% stake in KOPIN's Scottish subsidiary, which will serve as the foundation for a new European joint venture acting as the global (non-US) conduit for the production and distribution of AR-enabled systems co-developed between KOPIN and THEON and microLED display production . The whole investment in KOPIN of $15 million, is geared towards the co-development of products and reflects the belief by THEON, that the already extensive R&D investments that KOPIN has undertaken have established the necessary foundation, for a cooperation that can promptly translate into cost efficient, AR-enabled products.
This strategic partnership will also see THEON US subsidiary (T-Industries) moving their relevant industrial and product development operations at KOPIN's facility in Reston, VA, which shall become the US manufacturing hub for THEON's AR-enabled and future digital electro-optic products. As part of T-Industries' normal course of business, THEON, over the next five years, will be investing $8 million to support its US operations, as well as the new KOPIN -THEON co-development efforts. This new cooperation will not affect THEON's two existing partnerships in the night vision domain.
Secondly, THEON has signed a renewable minimum two-year supply agreement with eMagin, a US-based manufacturer of OLED micro-displays and virtual imaging technologies. eMagin specializes in high-resolution displays for military aviation, night vision, AR/VR, and other near-eye imaging applications. eMagin is a strategic supplier to THEON, providing most OLED displays used in THEON's products, including A.R.M.E.D. products, including foremost IRIS-C.
Thirdly, THEON has entered into a strategic partnership with ALEREON, a U.S.-based leader in Ultra-Wide-Band (UWB) wireless technology. ALEREON provides battle- proven UWB solutions that form the established Intra-Soldier communication protocol for the U.S. Army, enabling secure, jam-resistant communication between devices such as between THEON's THERMIS, THEA, IRIS-C, and ORION. Unlike conventional protocols like Wi-Fi or Bluetooth, ALEREON's UWB technology delivers unparalleled security, low latency, and resilience in battlefield conditions. Through this partnership, THEON will fully integrate UWB into its A.R.M.E.D. product line, produce it in Greece and will promote this unique solution in Europe and the Middle East as ALEREON's primary partner in the regions.
Lastly, THEON announces a strategic minority investment in Varjo Technologies Oy (VARJO), a Finnish deep-tech company specializing in Virtual Reality (VR) and Mixed Reality (MR) headsets and applications, deepening THEON's reach into the European innovation ecosystem. VARJO was founded in 2016 and supplies the most relevant aerospace and defense companies globally, delivering advanced military-grade VR/MR technology for training and simulation. The strategic collaboration between THEON and VARJO will combine THEON's technological know-how with VARJO'S advanced virtual and mixed reality hardware and software , with the companies having agreed to collaborate closely on multiple product and business initiatives. The agreement envisages an investment in VARJO via a €5 million convertible loan, structured to be converted into VARJO share capital upon the occurrence of defined events. THEON also holds an option to invest an additional €5 million under the same terms. This investment will support VARJO'S continued development of immersive technologies and reinforce THEON's digital expansion strategy under the THEON NEXT initiative, particularly on the development of high-tech products for defense applications.
Christian Hadjiminas, CEO of THEON, stated: 'Following the recent significant KAPPA acquisition, THEON has managed to sign such pioneering agreements, ensuring it retains its leading position in man-portable electro-optics. We are very proud that these arrangements bring the US and Europe closer together to develop the next generation of soldier-borne systems. The partnership initially involves operations in the United States, the United Kingdom, Finland as well as Greece and will be eventually enlarged into Germany and Belgium where our EU thermal/digital hub is being established. Together, we are pushing the frontier of Augmented Reality defense capabilities. These initiatives and investments will be further expanded upon during our announced Capital Markets Day to be held in Athens in November 2025 (details to be publicized). I am very proud of our commercial and R&D teams that have helped secure these agreements in a short time frame following a thorough review of essential technologies and potential partners over the past 12 months.'
Dimitrios Mandridis, CTO of Theon Sensors stated: 'THEON has managed to establish an advanced global technical cooperation framework combining all key technologies of the new inter-connected AR-capable-soldier era, as can be seen by the introduction of THEON's A.R.M.E.D. product line and its ever-growing adoption by modern armies. Every piece of this cooperation ensures that THEON will be at the forefront of new developments in the digital and AR technology space which further evolve THEON's A.R.M.E.D. product line for the benefit of our final customers. THEON's R&D department has been expanded and restructured to enable the integration of all these partnerships.'
Dimitris Parthenis, CFO of THEON, stated: 'Obtaining key technologies—especially when these relate to large companies also operating in the civil sector—through such agreements represents a flexible and financially efficient investment and rapid outcome for all our stakeholders. THEON's option to convert such development funds into equity positions would positively affect its future financial results. The current investment, totaling €25 million over two to five years, is expected to be paid back quickly, through enhancing the features and the price positioning of our current offer and also via the future growth of these companies that have some of the most promising civil and defense technologies. We are proud to be looking to the future with these compelling partners who share our leading entrepreneurial spirit.'
Michael Murray, CEO of KOPIN, stated: 'With defense investments accelerating globally, especially among European NATO allies, strategic partnerships have become critical to delivering next-generation, mission-ready technologies. We are proud to collaborate with THEON in a partnership that exemplifies innovation, agility, and shared purpose. By integrating KOPIN's cutting-edge micro-displays and application-specific optical subassemblies with Theon's advanced expertise in night vision, thermal imaging, and Electro-Optical ISR systems, we are not only meeting the evolving demands of modern defense operations, but we are also actively shaping the future of battlefield awareness and operational effectiveness.'
Amal Ghosh, CEO of eMagin stated: 'We are excited to partner with Theon, a leader in advanced optics and imaging systems, to integrate eMagin's state-of-the-art OLED microdisplay technology into their next generation of products. This collaboration underscores our shared commitment to delivering unmatched image quality, performance, and reliability for mission-critical applications. By combining eMagin's innovation in microdisplays with Theon's expertise in precision optics, we are poised to create solutions that set a new standard in the field and deliver exceptional value to customers worldwide.'
David Shoemaker, CEO of ALEREON, stated: 'We're excited to partner with THEON and be part of this forward-looking initiative. THEON'S proven expertise in electro-optics and extensive international business development network make them an ideal ally in expanding the reach and implementation of ALEREON's UWB technology. With THEON as our key partner in Europe and the Middle East, we look forward to bringing our battle- proven communication solutions into the hands of many more allied soldiers.'
Timo Toikkanen, CEO of VARJO, added: 'We are proud to welcome THEON as a strategic investor in VARJO. Since our inception, VARJO has been creating the most advanced VR/XR military systems globally. THEON's extensive experience and leadership in the defense sector make them an ideal partner as we expand our impact in mission-critical training and simulation, enabling unprecedented levels of realism, readiness, and operational effectiveness.'
For inquiries, please contact:
Investor RelationsNikos Malesiotis
E-Mail: [email protected]
Tel: +30 210 6772290
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a minute ago
- Business Wire
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its first quarter ended June 30, 2025, and is pleased to provide an update on key business milestones. 'With our recently announced funding agreement in place, we are well positioned to continue advancing our lead clinical programs, CYB003 and CYB004, through multiple inflection points,' said Doug Drysdale, Chief Executive Officer of Cybin. 'Gaining European CTA approval and MHRA approval to commence EMBRACE in the UK has enabled us to expand our multinational Phase 3 PARADIGM program evaluating CYB003 for the potential adjunctive treatment of major depressive disorder. PARADIGM is a significantly larger program than the completed Phase 2 study, with anticipated combined enrollment of approximately 550 participants. Our Phase 3 studies will evaluate the potential clinical benefits of CYB003 in patients living with moderate to severe MDD, and whose symptoms are uncontrolled with existing antidepressant treatment. Our Phase 2 study evaluating CYB004 in generalized anxiety disorder is expected to complete patient enrollment this month.' 'Cybin is in a strong position to advance our programs and continue our work to deliver innovative therapies to address some of the most challenging mental health disorders we face today and is helping to build momentum across the sector - both from a clinical and regulatory perspective,' concluded Drysdale. Recent Business and Pipeline Highlights: Received European approval and MHRA approval for EMBRACE, the second Phase 3 study within the PARADIGM program evaluating CYB003 for the adjunctive treatment of MDD, on schedule. The Company has received CTA approval from the Irish Medicines Board for the EMBRACE study in Ireland, Poland, and Greece, as well as approval from the MHRA. EMBRACE is a 12-week, randomized, double-blind, placebo-controlled study in 330 participants with moderate to severe MDD (MADRS≥24) who are on a stable dose of antidepressant medication but with inadequate response. EMBRACE will evaluate two doses of CYB003 (8 mg, 16 mg) three weeks apart, compared to an inactive placebo. The primary endpoint is change in depressive symptoms as measured by the change in MADRS from baseline six weeks after the first dose. Making strong progress on CYB003 development through the APPROACH and EXTEND studies. Dosing is currently ongoing in the first pivotal study, APPROACH, which is expected to enroll 220 patients across 45 U.S. clinical sites. We are pleased to report that patient rollovers continue into EXTEND, the long-term extension study. Clinical Program Summary CYB003: Deuterated psilocin program Phase 3 PARADIGM program is underway, with topline data from first pivotal study, APPROACH, expected in 2026 1. CYB003 program accomplishments: Received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of MDD. A completed Phase 2 study of CYB003 in MDD demonstrated durability of effect at 12 months: 100% of participants receiving two doses of 16 mg were responders. 71% of participants receiving two doses of 16 mg were in remission. Mean change from baseline in MADRS was approximately -23 points after two 16 mg doses. CYB004: Deuterated dimethyltryptamine program The Phase 2 CYB004 study is a randomized, double-blind study evaluating the safety and efficacy of CYB004 in participants with generalized anxiety disorder, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed. Patient enrollment is expected to be completed this month 1. Change in Presentation Currency Effective April 1, 2025, the Company changed its presentation currency from the Canadian dollar to the United States dollar (' USD '). The change in presentation currency was made to better reflect the Company's operations, align with the currency in which the majority of cash-based expenses are denominated, and improve comparability of its financial results with other publicly traded businesses in the industry. As a result, all amounts presented in this press release are in USD unless otherwise stated. First-Quarter Financial Highlights Cash totaled $118.7 million as of June 30, 2025. Net loss was $24.6 million for the quarter ended June 30, 2025, compared to a net loss of $10.8 million in the same period last year. Cash-based operating expenses consisting of research, general, and administrative costs totaled $23.9 million for the quarter ended June 30, 2025, compared to $11.9 million, in the same period last year. Cash flows used in operating activities were $29.5 million for the quarter ended June 30, 2025, compared to $19.9 million in the same period last year. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Note: There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See 'Cautionary Notes and Forward-Looking Statements'. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the EMBRACE study to enroll 330 participants at approximately 60 clinical sites across the United States, United Kingdom, Europe, and Australia; the Company's expectation to enroll 220 participants at approximately 45 clinical sites across the United States for the APPROACH study; the Company's expectation to complete enrollment in CYB004 Phase 2 study in August 2025; the Company's expectation to receive topline data from APPROACH in 2026; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2025, and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
San Francisco Chronicle
a minute ago
- San Francisco Chronicle
Kimball Electronics: Fiscal Q4 Earnings Snapshot
JASPER, Ind. (AP) — JASPER, Ind. (AP) — Kimball Electronics Inc. (KE) on Wednesday reported net income of $6.6 million in its fiscal fourth quarter. The Jasper, Indiana-based company said it had net income of 26 cents per share. Earnings, adjusted for one-time gains and costs, were 34 cents per share. The electronics manufacturing services company posted revenue of $380.5 million in the period. Kimball Electronics expects full-year revenue in the range of $1.35 billion to $1.45 billion. _____
Bloomberg
2 minutes ago
- Bloomberg
Trump's Deal With Nvidia Offers Path Forward in Global Trade War
President Donald Trump's controversial plan to take a cut of revenue from chip sales to China has US companies reconsidering their plans for business with the country, offering a model for circumventing years of trade tensions. Experts and people familiar with the matter said the surprise deal, in which Nvidia Corp. and Advanced Micro Devices Inc. agreed to pay 15% of their revenues from Chinese AI chip sales to the US, provides a path to enter the Chinese market despite severe export controls, tariffs and other trade barriers.
